Hi Bhupinder:
Great question and I think Richard has put the issues well.
If you want to go the letter to file route, I would get a "regulatory opinion/position" from a local regulatory lawyer to confirm the interpretation and do some usability to show there is no demonstrable addition risk from adding the new group of prescribers (e.g. 10 ficticous situations with a question like, "do you prescribe or not and why?"). There is a risk that an FDA inspector might not agree, but my experience is if you have documented a good/believable/viable case for your interpretation of the law, you rarely get into trouble!
If you want to play it safe, I think a new traditional citing this as a new indication. Maybe you could consolidate with other changes to make the effort more worthwhile.
As you can probably infer, I do not like the middle path of a special. It is a half-way house, but one you are almost certainly "a little bit wrong": either you could of done a letter to file or you need to add a new indication.
Personally, I relish a fight; so if I can get a lawyer's letter to support my interpretation and a simple usability looks good, I would most likely go the letter to file route! As always "the Devil may be in the detail" so do check how the change is affected and the labeling!
Last thought, these questions are never easy .... but they are how you win "your spurs" in an organization!
Good luck whatever you decide!
Neil
------------------------------
Neil Armstrong FRAPS
CEO MeddiQuest Limited
Peterborough
United Kingdom
------------------------------
Original Message:
Sent: 14-Dec-2022 10:56
From: Bhupinder Singh
Subject: Letter to File vs Special 510(K)
Hello RAPS Community,
I need your advice. The device is classified as Class II SaMD (ADHD). Only physicians are allowed to prescribe the device under FDA's special control. It is now the organization's goal to expand its prescriber group to include licensed healthcare professionals (such as nurse practitioners, psychologists, etc.). According to my thought process, this should be a special 510(K), but a few members of the organization believe this would be a letter to file in accordance with FDA guidance (when to submit a 510(K). I would greatly appreciate any guidance you can provide here. Thanks,
------------------------------
Bhupinder Singh
QA/RA Manager (RAC)
San Jose CA
United States
------------------------------